Kiora Pharmaceuticals Inc. (KPRX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing therapies for ophthalmic diseases. This report covers the quarterly period ended September 30, 2025. The Company is classified as a smaller reporting company. As of November 5, 2025, there were 3,677,935 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $16,020,000 |
| Net (Loss) Income | $26,806 | $(3,413,326) | $(4,318,633) | $7,818,235 |
| Operating Expenses | $794,437 | $3,602,237 | $5,520,987 | $8,945,030 |
| Research & Development (Gross) | $2,729,891 | $2,184,991 | $7,852,267 | $5,917,868 |
| Cash & Short-Term Investments | $19,375,445 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(147,700,755) (as of Sept 30, 2025) |
Liquidity: The Company held $5.5 million in cash and cash equivalents and $13.9 million in short-term investments as of September 30, 2025. Management anticipates sufficient cash to fund planned operations into late 2027.
Material Changes vs. Prior Period
- Revenue: Revenue was $0 for the three and nine months ended September 30, 2025, compared to $16.0 million in collaboration revenue recognized in the first quarter of 2024 from the Théa Open Innovation (TOI) agreement. No collaboration revenue was recognized in Q3 2025.
- Net Income: The Company reported a net income of $26,806 for Q3 2025, a significant improvement from the net loss of $3.4 million in Q3 2024. This shift was driven by a $1.7 million reduction in the fair value of contingent consideration and the absence of the $2.0 million in-process R&D impairment recorded in 2024.
- Operating Expenses: Total operating expenses decreased significantly year-over-year due to the non-recurring impairment charge in 2024 and favorable changes in the fair value of contingent consideration. However, gross R&D expenses increased by $0.5 million in Q3 and $1.9 million YTD, primarily due to clinical trial activities for KIO-301 and KIO-104.
- Collaboration Credits: Collaboration credits (reimbursements from TOI) increased to $1.66 million in Q3 2025 from $0.87 million in Q3 2024, offsetting a portion of the increased R&D spend.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur significant expenses and increasing operating losses for the foreseeable future. Based on current cash and short-term investments, the Company believes it can fund operations into late 2027 without immediate need for additional capital.
- Product Pipeline:
- KIO-301: Phase 2 trial (ABACUS-2) for retinitis pigmentosa began enrollment in Q2 2025 and dosing in Q3 2025. An exclusive option agreement with Senju Pharmaceutical for Asian rights was signed in May 2025, generating a $1.25 million deferred revenue payment.
- KIO-104: Phase 2 trial for retinal inflammation began enrollment in Q2 2025 and dosing in Q3 2025.
- KIO-101: Development is paused; the asset is available for partnership.
- Risks: The Company has a history of losses and negative cash flows. Future losses are anticipated. There is no assurance that additional financing will be available on acceptable terms if needed before late 2027. Success depends on clinical trial results and regulatory approvals.
- Unusual Items: The Q3 2024 results included a $2.0 million impairment of KIO-201 assets due to a strategic decision to cease development. No such impairment occurred in 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $19.4 million in liquid assets to fund operations through late 2027, considering potential acceleration of clinical trial costs.
- Deferred Revenue: Confirm the recognition timeline for the $1.25 million upfront payment from the Senju option agreement, which is currently deferred.
- Contingent Consideration: Monitor the fair value adjustments of contingent consideration liabilities ($2.9 million), which significantly impact net income volatility.
- Reimbursement Timing: Review the timing of R&D expense reimbursements from TOI to ensure cash flow alignment with incurred costs.
- Clinical Milestones: Track the progress and topline data release dates for the ABACUS-2 (KIO-301) and KIO-104 Phase 2 trials, expected in 2026.